Phase 1/2 Study of Treatment Response With VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor, in Patients with Thyroid Eye Disease (TED)
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE(2023)